Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic is a clinical-stage biopharmaceutical company with a promising pipeline of selective oral immunology therapies that target chronic inflammatory and autoimmune diseases like ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company has a strong focus on safety and efficacy factors in their treatment selection, and their lead product candidate, vidofludimus calcium, has shown promising results in Phase 2 clinical trials for relapsing-remitting multiple sclerosis (RRMS). They also have a robust research and development program for other indications like secondary progressive MS (SPMS) and primary progressive MS (PPMS), which have high unmet medical needs and large addressable markets. With a clean safety profile and potential market penetration in the RMS market, Immunic has the potential for significant upside and a favorable patient benefit/risk profile compared to current treatment options.

Bears say

Immunic is a clinical-stage biopharmaceutical company with a negative outlook, primarily due to concerns about the success of its pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases such as ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company's current products, IMU-838, IMU-935, and IMU-856, target specific immune pathways but have shown limitations in previous clinical trials. Additionally, the company faces potential competition and limited market penetration in the highly competitive and crowded field of multiple sclerosis treatments. Financially, Immunic has a high cash burn rate and may require additional funding in the future to continue development. The recent hiring of a new CMO and Vice President of Business Development does not guarantee success, and there is potential for significant downside risk in the stock price if clinical trials do not meet expectations.

Immunic Inc (IMUX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.